<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823797</url>
  </required_header>
  <id_info>
    <org_study_id>6803</org_study_id>
    <secondary_id>NCI-2010-00714</secondary_id>
    <secondary_id>6803</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00823797</nct_id>
  </id_info>
  <brief_title>Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma</brief_title>
  <official_title>A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well bendamustine hydrochloride works in treating patients
      with anaplastic glioma or glioblastoma that has come back (recurrent) or growing, spreading
      or getting worse (progressive). Drugs used in chemotherapy, such as bendamustine
      hydrochloride, work in different ways to stop the growth of tumor cells, either by killing
      the cells or by stopping them from dividing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. The primary endpoint for this study is the 6-month progression-free survival-i.e., the
      proportion of patients who remain alive and free of any tumor progression at 6 months.

      SECONDARY OBJECTIVES:

      I. To determine the safety of single agent bendamustine (Treanda) (bendamustine
      hydrochloride) the treatment of malignant gliomas.

      II. To determine the efficacy of bendamustine (Treanda) as a single agent as assessed by
      progression-free survival (PFS) at 6 months.

      III. To assess quality of life using the Functional Assessment of Cancer Therapy-Brain
      (FACT-BR).

      OUTLINE:

      Patients receive bendamustine hydrochloride intravenously (IV) over 30-90 minutes on days
      1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days and then every 2
      months for up to 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS-6</measure>
    <time_frame>At 6 months</time_frame>
    <description>Defined as the proportion of patients who remain alive and free of any disease progression at 6 months. PFS over time will be estimated using the Kaplan-Meier method with standard errors estimated using Greenwood's formula.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to progression or death, whichever came first, assessed up to 108 months</time_frame>
    <description>Defined as the time from date of initial therapy to first objective documentation of tumor progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxic Death</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Defined as death that is possibly, probably, or definitely attributed to bendamustine hydrochloride.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Until death or last reported survival</time_frame>
    <description>*inclusive of subjects still alive at time of last reporting.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Adult Anaplastic Astrocytoma</condition>
  <condition>Adult Anaplastic Oligodendroglioma</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Recurrent Adult Brain Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (bendamustine hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bendamustine hydrochloride)</arm_group_label>
    <other_name>Bendamustin Hydrochloride</other_name>
    <other_name>Cytostasan Hydrochloride</other_name>
    <other_name>Levact</other_name>
    <other_name>Ribomustin</other_name>
    <other_name>SyB L-0501</other_name>
    <other_name>Treanda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (bendamustine hydrochloride)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must have had prior pathologic confirmation of tumor histology,
             anaplastic glioma (AG) or glioblastoma (GBM) and have supratentorial gliomas

          -  Patients must have shown unequivocal evidence for tumor recurrence or progression by
             magnetic resonance imaging (MRI) or computed tomography (CT) scan with contrast

          -  The recurrence to be treated needs to be the 1st or 2nd recurrence of the AG or GBM

          -  If a patient has had surgery prior to enrolling on study, an enhanced MRI or CT scan
             should be done within 96 hours prior to surgery or at least 4-6 weeks after surgery

          -  Patients having undergone recent resection of recurrent or progressive tumor will be
             eligible as long as all of the following conditions apply:

               -  They are &gt; 2 weeks from surgery

               -  They have recovered from the effects of surgery

               -  Evaluable or measurable disease following resection of recurrent tumor is
                  mandated for eligibility into the study

               -  To best assess the extent of residual disease post-operatively, an enhanced
                  CT/MRI should be done no later than 96 hours after surgery or it will need to be
                  done 4-6 weeks post-operatively; if the 96 hour scan is more than 2 weeks from
                  registration, the scan needs to be repeated

          -  A baseline scan should be performed within 14 days prior to registration and on a
             steroid dosage that has been stable for at least 5 days otherwise a new baseline MR/CT
             is required; the same type of scan, i.e., MRI or CT must be used throughout the period
             of protocol treatment for tumor measurement

          -  Patients must have failed prior external beam radiation therapy; a positron emission
             tomography (PET) or thallium single photon emission computed tomography (SPECT), MR
             spectroscopy and MR perfusion, or surgical documentation may be done at the discretion
             of the treating physician if there is a question of radiation changes/necrosis versus
             progressive disease

          -  Stereotactic radiosurgery (SRS):

               -  Patients must have confirmation of true progressive disease rather than radiation
                  necrosis based upon either PET or Thallium SPECT, MR spectroscopy and MR
                  perfusion or surgical documentation of disease

               -  At least 12 weeks between completion of SRS and initiation of bendamustine

          -  Interstitial brachytherapy: patients must have confirmation of true progressive
             disease rather than radiation necrosis based upon either PET or Thallium SPECT, MR
             spectroscopy and MR perfusion or surgical documentation of disease

          -  Patients must have had at least one prior chemotherapy regimen that included
             temozolomide and no more than one prior salvage chemotherapy

          -  Patients must have recovered from the toxic effects of prior therapy: 4 weeks from
             prior cytotoxic therapy and/or at least 2 weeks from vincristine, 6 weeks from
             nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic
             agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc.
             (radiosensitizer does not count), 4 weeks for experimental biologic agents (epidermal
             growth factor receptor [EGFR] inhibitors, etc) and 7 weeks from Gliadel implantation

          -  All patients must sign an informed consent indicating that they are aware of the
             investigational nature of this study; patients must sign an authorization for the
             release of their protected health information

          -  Patients must have a life expectancy &gt; 11 weeks

          -  Patients must have a Karnofsky performance status of &gt; 60

          -  White blood cells (WBC) &gt;= 3,000/ul

          -  Absolute neutrophil count (ANC) &gt;= 1,500/mm^3

          -  Platelet count &gt;= 80,000/mm^3

          -  Hemoglobin &gt;= 9 mg/dl (NOTE: eligibility level for hemoglobin may be reached by
             transfusion)

          -  Absolute lymphocyte count &gt;= 200/mm^3

          -  Serum glutamic oxaloacetic transaminase (SGOT)/serum glutamate pyruvate transaminase
             (SGPT) &lt; 3 times upper limit of normal (ULN)

          -  Bilirubin &lt; 1.5 times ULN

          -  Serum creatinine &lt; 1.5 mg/dL

          -  Calculated creatinine, glomerular filtration rate (GFR) &gt;= 30 cc/minute

        Exclusion Criteria:

          -  Patients must not have any significant medical illnesses that in the investigator's
             opinion cannot be adequately controlled with appropriate therapy or would compromise
             the patient's ability to tolerate this therapy

          -  Known human immunodeficiency virus (HIV)-positive patients receiving combination
             anti-retroviral therapy are excluded from the study

          -  Patients with a history of any other cancer (except non-melanoma skin cancer or
             carcinoma in-situ of the cervix), unless in complete remission and off of all therapy
             for that disease for a minimum of 3 years are ineligible

          -  Patients must not be pregnant or breast feeding and must practice adequate
             contraception

          -  Patients can only be on non-enzyme inducing anti-convulsants; if they are on an enzyme
             inducing anti-convulsant, they may be converted to a non-enzyme inducing
             anticonvulsants

          -  Patients cannot be taking any cytochrome P450, cytochrome P450, family 1, subfamily A,
             polypeptide 2 (CYP1A2) pathway inhibiting or inducing agents (except proton pump
             inhibitors which are allowed) including cimetidine, antidepressants, antibiotics and
             all others

          -  Known sensitivity to bendamustine

          -  Known sensitivity to mannitol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maciej Mrugala</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <results_first_submitted>April 7, 2017</results_first_submitted>
  <results_first_submitted_qc>April 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2017</results_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Maciej Mrugala</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma</title>
          <description>Anaplastic Glioma Arm
Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Treatment (Bendamustine Hydrochloride) for Glioblastoma</title>
          <description>Glioblastoma Arm
Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma</title>
          <description>Anaplastic Glioma Arm
Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Treatment (Bendamustine Hydrochloride) for Glioblastoma</title>
          <description>Glioblastoma Arm
Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PFS-6</title>
        <description>Defined as the proportion of patients who remain alive and free of any disease progression at 6 months. PFS over time will be estimated using the Kaplan-Meier method with standard errors estimated using Greenwood's formula.</description>
        <time_frame>At 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Bendamustine Hydrochloride) for Glioblastoma</title>
            <description>Glioblastoma Arm
Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma</title>
            <description>Anaplastic Glioma Arm
Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS-6</title>
          <description>Defined as the proportion of patients who remain alive and free of any disease progression at 6 months. PFS over time will be estimated using the Kaplan-Meier method with standard errors estimated using Greenwood's formula.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS</title>
        <description>Defined as the time from date of initial therapy to first objective documentation of tumor progression or death.</description>
        <time_frame>Up to progression or death, whichever came first, assessed up to 108 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Bendamustine Hydrochloride) for Glioblastoma</title>
            <description>Glioblastoma Arm
Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma</title>
            <description>Anaplastic Glioma Arm
Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS</title>
          <description>Defined as the time from date of initial therapy to first objective documentation of tumor progression or death.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-0.5" upper_limit="2.6"/>
                    <measurement group_id="O2" value="2.6" lower_limit="-1.0" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxic Death</title>
        <description>Defined as death that is possibly, probably, or definitely attributed to bendamustine hydrochloride.</description>
        <time_frame>Up to 30 days after completion of study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Bendamustine Hydrochloride) for Glioblastoma</title>
            <description>Glioblastoma Arm
Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma</title>
            <description>Anaplastic Glioma Arm
Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Toxic Death</title>
          <description>Defined as death that is possibly, probably, or definitely attributed to bendamustine hydrochloride.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>*inclusive of subjects still alive at time of last reporting.</description>
        <time_frame>Until death or last reported survival</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Bendamustine Hydrochloride) for Glioblastoma</title>
            <description>Glioblastoma Arm
Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma</title>
            <description>Anaplastic Glioma Arm
Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>*inclusive of subjects still alive at time of last reporting.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="8.2" upper_limit="28.4"/>
                    <measurement group_id="O2" value="45.6" lower_limit="33.6" upper_limit="57.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Bendamustine Hydrochloride)</title>
          <description>Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
Bendamustine Hydrochloride: Given IV
Quality-of-Life Assessment: Ancillary studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maciej Mrugala, MD, PhD, MPH</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-543-4069</phone>
      <email>mmrugala@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

